Business Wire

OCTO Acquires Nebula Systems, Reinforces Its Leadership in Intelligent Vehicle Diagnostics

Share

OCTO Telematics, the leading global provider in transforming an IoT Big Data set into actionable intelligence, has acquired the entire share capital of Nebula Systems Ltd.

Nebula specialises in the development of advanced cloud technologies for the automotive and connected car industries. This means that its proprietary technologies are now available to make vehicle systems and data more accessible, so that a vehicle’s health, status and operation can be monitored, analysed, diagnosed and maintained, faster and more effectively than ever before - anytime and anywhere.

OCTO continues its investment strategy in companies with high technological value, pursuing continuous portfolio innovation and market leadership. The acquisition confirms OCTO’s unwavering commitment to respond to the increasing demand for vehicle usage data analysis tools, with advantages for insurance, automotive and mobility companies with its increasingly integrated and complete offering.

Modern cars are full of sensors that generate huge amounts of valuable data that can be used to enhance both the driver and fleet manager experience. The vast majority of this data is related to OEM Electronic Control Unit (ECU), protocol and CAN bus which are difficult for the aftermarket to access. The Nebula Systems diagnostic cloud solution is based on an integrated circuit and a suite of vehicle data analysis software applications in order to better respond to the increased complexity. An integrated circuit, developed with proprietary technology, grants deep access to OEM level data. Vehicle telematics can therefore benefit from combining this telematics chipset with proprietary analysis software, which gives OCTO the ultimate flexibility and ease of access to OEM vehicle data by using a unique VIN-specific configuration file that contains the instructions to read Parameter ID (PID) sets from any OEM ECU on virtually any car.

This technology uniquely combines the proprietary chipset and a cloud-based VIN interpreter and configuration files builder to fully access all the ECUs and thousands of PIDs a vehicle may have.

“We are very proud of this latest acquisition which places OCTO amongst the leading providers of fleet telematics leasing and renting organizations” says Nicola Veratelli, OCTO Group CEO. “Amongst many trends that are changing the mobility sector there are some that have a significant impact on fleet managers, such as the need to integrate data coming from the vehicle, each different from the other and defined for each manufacturer. OCTO solves the complexity of interpreting this data and offers impactful solutions which contribute to deliver additional value for fleet managers. We are committed to offer dozens of fleet telematics services to fleet managers and drivers: remote cloud-based diagnostics deriving from this Nebula acquisition is surely one of the most relevant.”

With this acquisition, the Nebula technology will be integrated in the standard OCTO offering. Furthermore, all OCTO telematics devices will integrate these capabilities, allowing OCTO solutions full access to all OEM ECUs and to use diagnostic trouble codes and Parameter IDs for the benefit of both drivers and fleet managers. The combination of these benefits will have a substantial impact on mobility management costs for fleet managers using the OCTO Fleet Telematics solution.

About OCTO
Founded in 2002, OCTO is today the Number 1 global provider of telematics and data analytics solutions for the auto insurance industry and, increasingly, a major player in Fleet management services, with world-class solutions to grow its core businesses – Insurtech and Intelligent Mobility – and to expand and provide innovative connected solutions in new industries and international markets.
OCTO’s vision is to connect the world of mobility through advanced analytics and IoT-driven services for a new era of Smart Telematics.
OCTO currently has 6 million connected users, holds the largest global database of telematics data, with more than 248 billion miles of driving data collected and over 464,000 crashes and insurance events analysed, and runs more than 10 car sharing services with more than 400,000 hires per month.

Contact information

OCTO Telematics
Adriana Zambon
press.it@octotelematics.com
m: +39 339.3995640

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom